Kay C R
Am J Obstet Gynecol. 1982 Mar 15;142(6 Pt 2):762-5. doi: 10.1016/s0002-9378(16)32485-1.
In the course of a large-scale prospective study of the health of oral contraceptive users, the rate of reporting of arterial diseases was examined in two groups of users of pill brands that permitted the effect of the progestogen to be assessed independently of estrogen effect. The rate of reporting was consistently higher with the brands with the higher progestogenic activity. The reports of cerebrovascular diseases showed a significant trend in relation to the dose of norethindrone acetate as well as in relation to total arterial diseases. Total arterial diseases were also reported more frequently in association with brands containing 250 microgram of levonorgestrel than with those containing 150 microgram of this progestogen. The mean serum levels of high-density lipoprotein cholesterol in users of the brands described show a striking inverse relationship to the rate of reporting of arterial diseases and to the progestogenic activity of the pills.
在一项关于口服避孕药使用者健康状况的大规模前瞻性研究过程中，对两组使用不同品牌避孕药的人群进行了动脉疾病报告率的检查，这些品牌的避孕药能够独立评估孕激素的作用而不受雌激素作用的影响。具有较高孕激素活性的品牌的报告率始终较高。脑血管疾病的报告显示，与醋酸炔诺酮剂量以及总动脉疾病相关存在显著趋势。与含150微克左炔诺孕酮的品牌相比，含250微克左炔诺孕酮的品牌报告的总动脉疾病也更频繁。所述品牌使用者的高密度脂蛋白胆固醇平均血清水平与动脉疾病报告率以及避孕药的孕激素活性呈显著负相关。
